Leukocyte-derived biomimetic nanoparticulate drug delivery systems for cancer therapy.

about

Leukocyte-derived biomimetic nanoparticulate drug delivery systems for cancer therapy.

Item

http://www.wikidata.org/entity/Q55150815

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Leukocyte-derived biomimetic nanoparticulate drug delivery systems for cancer therapy.

@en

Leukocyte-derived biomimetic nanoparticulate drug delivery systems for cancer therapy.

@nl

type

Item

label

Leukocyte-derived biomimetic nanoparticulate drug delivery systems for cancer therapy.

@en

Leukocyte-derived biomimetic nanoparticulate drug delivery systems for cancer therapy.

@nl

prefLabel

Leukocyte-derived biomimetic nanoparticulate drug delivery systems for cancer therapy.

@en

Leukocyte-derived biomimetic nanoparticulate drug delivery systems for cancer therapy.

@nl

P1476

Leukocyte-derived biomimetic nanoparticulate drug delivery systems for cancer therapy.

@en

P2093

Jun Chen

http://www.w3.org/2001/XMLSchema#string

Xiaoling Gao

http://www.w3.org/2001/XMLSchema#string

Yukun Huang

http://www.w3.org/2001/XMLSchema#string

P2860

Neutrophils responsive to endogenous IFN-beta regulate tumor angiogenesis and growth in a mouse tumor model

Targeted and effective photodynamic therapy for cancer using functionalized nanomaterials

Nanocarrier-mediated co-delivery of chemotherapeutic drugs and gene agents for cancer treatment

Cell-based drug delivery

Chemokine: receptor structure, interactions, and antagonism

Human T, B, natural killer, and dendritic cells arise from a common bone marrow progenitor cell subset

CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis

Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN

Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions

The Immunogenicity and Immune Tolerance of Pluripotent Stem Cell Derivatives.

P304

4-13

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.APSB.2017.12.001

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29872618

http://www.w3.org/2001/XMLSchema#string

P921

drug delivery

nanoparticle

P932

5985693

http://www.w3.org/2001/XMLSchema#string